Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter study.
Mark E Gormley, Edward Dabrowski, Mauricio R Delgado and 5 others
PMID 40745401WHAT IT FOUND
In children with lower limb spasticity, abobotulinumtoxinA helped most patients reach their specific functional goals.
Goal achievement remained high through eight injection cycles, with ambulatory patients doing better than non-ambulatory ones.
Key findings
01The mean cumulative Goal Attainment Scale T-score was 51.1, indicating that patients generally achieved their treatment goals as expected or slightly better.
0274.8% of patients achieved their primary goal after the first injection cycle, and more than 60% continued to achieve it through the eighth cycle.
03Ambulatory patients demonstrated greater goal achievement than non-ambulatory patients, although both groups benefited.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was observational with no control group, so it cannot prove that abobotulinumtoxinA caused the improvements; natural history or concomitant therapies may have contributed. There was a high dropout rate, with 29.5% of the effectiveness population withdrawing, primarily due to lost to follow-up or administrative reasons, which may bias results. Patients received various concomitant therapies, including physical therapy, occupational therapy, and casting, making it difficult to isolate the effect of the injection alone. The study was funded by the manufacturer (Ipsen), and several authors have financial relationships with the company or competitors. Disease assessment methods were not standardized across the 27 sites, and the GMFCS classification was used for patients with non-CP etiologies of spasticity.
Declared interests
The study was funded by Ipsen, the manufacturer of abobotulinumtoxinA. Multiple authors declared financial relationships including consulting fees, research support, or employment with Ipsen and other botulinum toxin manufacturers.
The easy way to misread this
Do not interpret the high goal attainment rates as proof of efficacy compared to no treatment. This was an observational study without a control group, and most patients were also receiving physical or occupational therapy and casting. The improvements reflect real-world use alongside these other interventions.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →